Navigation Links
Data Presented at the American Academy of Neurology's Annual,Meeting Provide Update on Utilization and Safety of Tysabri in,Patients with Multiple Sclerosis

ts who entered the extension study, which includes approximately 250 patients with nearly three years of continuous therapy).

In addition, TYSABRI also decreased the cumulative probability of disability progression sustained for six months compared to placebo. The estimated proportion of patients who had 24-week sustained disability progression at two years was 11% in patients treated with TYSABRI compared to 23% in patients treated with placebo, a 54% relative reduction.

This effect was maintained in patients treated with TYSABRI for up to three years with 13% showing 24-week sustained disability progression.

About TOUCH and TYGRIS

Before initiating treatment, all US patients, prescribers and infusion sites must be enrolled in the TOUCH Prescribing Program (TYSABRI Outreach: Unified Commitment to Health). TOUCH is designed to determine the incidence of and risk factors for serious OIs, including PML, and to monitor patients for signs and symptoms of PML while promoting informed benefit/risk discussions prior to initiating TYSABRI treatment. Physicians report on PML, serious OIs, deaths and discontinuation of therapy on an ongoing basis.

TYGRIS (TYSABRI Global ObseRvation Program In Safety) is expected enroll 5,000 patients worldwide, including approximately 3,000 patients from TOUCH. Patients in TYGRIS are evaluated at baseline and every six months thereafter for five years. Researchers will evaluate data including medical/MS history; prior TYSABRI use; prior use of immunomodulatory, antineoplastic, or immunosuppressive agents; and all serious adverse events, including PML and other serious OIs, and malignancies.

The information provided here is derived from voluntary adverse event reporting. It is possible that not all reactions have been reported, or that some reactions are not reported to Biogen Idec or Elan in a timely manner.

About TYSABRI

In the US, TYSABRI is approved as a monotherapy treatment for rela
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:12/1/2008)...O, Dec. 1 TargeGen has announced t...from a multi-center, US-based clinical,trial of T... been scheduled at,the 2008 American Society of H... presentation are as follows:, Title: ...vailable, JAK2-Selective I...
(Date:12/1/2008)...stinence is still the best policy , , ROCH...new study from Mayo Clinic finds the use of the dr...holic hepatitis, an acute inflammation of the live...results of the study are published in the December...urnal.org/ ). , , VIDEO ALERT: Additional ...
(Date:12/1/2008)...O, Dec. 1 Vical Incorpor... of a $1.0 million milestone payment from Merck &a...of a Phase I clinical trial of an investigational ...accine is based on Vical,s DNA gene delivery techn...iptase (hTERT). hTERT is the subject of separate l...
(Date:11/27/2008)...y finds the majority of acute lymphoblastic leukem... at the time of diagnosis , , MEMPHIS, Tenn...t St. Jude Children,s Research Hospital have ident...lls of children with acute lymphoblastic leukemia ...hway to designing treatments for ALL relapse in ch...
Breaking Medicine Technology:Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3Progress toward new storage media 8631 1Progress toward new storage media 8631 2Anadys Pharmaceuticals to Present at Bio Investor Forum 27824 1Anadys Pharmaceuticals to Present at Bio Investor Forum 27824 2MU researchers advance health communication for at risk populations 27821 1MU researchers advance health communication for at risk populations 27821 2Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference 3354 1Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference 3354 2Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference 3354 3Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference 3354 4
... Since the level of blood oxygenation can be an es... of hemoglobin levels in the clinical setting is o...o incorporate sophisticated technology into easily...several manufacturers offer prompt assessment of h..., Calif., says that its HemoCue Hemoglobin Test Sy...
... Although it may still seem radically innovative i...ated production in the manufacturing sector had be..., for example, automated lines fabricate sub-assem...an oversight. The result has been vastly improved ...ive returns in profit and productivity. These days...
Other Medicine Technology:Hemoglobin Testing at the Point of Care 2Hemoglobin Testing at the Point of Care 3Lab Automation Networks Proliferating 2Lab Automation Networks Proliferating 3Lab Automation Networks Proliferating 4
(Date:12/2/2008)...c. 2 Aduromed Industries...ider of medical waste treatment,systems, today an...n November,24, 2008 to protect the Company,s prop...rized MedClean Systems that provide a turnkey solu...tion and volume reduction. , The patent app...
(Date:12/2/2008)... Dec. 2 Genoptix, Inc. (...s provider, today announced the Company,s particip...onference scheduled to take place at the Westin Ne...08. , , Sam Riccitelli, COO and executive...anel discussion at the conference on Wednesday, De...
(Date:12/2/2008)...f., Dec. 2 In response to the comm..., Frequent Respiratory Infections, and the Vitamin... by 16 well known supplement experts, Nordic Natur...s pose no threat or compromise to consumers and ac...at are low in natural Vitamin A. According to Kari...
(Date:12/2/2008)...alif., Dec. 2 Internationally reco...as an invited speaker for this,year,s annual meet..., (Photo: http://www.newscom.com/cgi-bin/p...,Why is minimally invasive (or ,Goldilocks,) anest...tled ,PK 101, minimally invasive,anesthesia for m...
Breaking Medicine News(10 mins):Health News:Aduromed Files Patent Application to Cover Proprietary New Standard for Containerized, Turnkey Solution 2Health News:Aduromed Files Patent Application to Cover Proprietary New Standard for Containerized, Turnkey Solution 3Health News:Genoptix Announces Participation at the RBC Capital Markets 2008 Healthcare Conference 2Health News:Nordic Naturals Offers Cod Liver Oil Solutions in Response to Recent Vitamin A and Vitamin D Controversy 2
...ment has repeated its plea to doctors over prescri...could save ?85 millions in the coming year if GPs/... Primary Care Trusts (PCTs) can prescribe generic ...mvastatin, which are two of five ‘statin’ drugs th...
...exercise by doing household chores like dusting, m...east cancer, suggests a new study.// The research... women from nine European countries and found that... cancer protective than playing sport, reported th...
...s at the National Institutes of Health have discov...steogenesis //Imperfecta--a disorder that weakens ...lts from a genetic defect in a protein involved in...ted gene contains the information for cartilage as...
... your high blood pressure might just be your infla...dence suggests that inflammation, a part of the im...r, Alzheimer’s and diabetes, may also help transla...ressure. “There is a concept that hypertension is...
Other Medicine News:Health News:Researchers Discovered the Gene Responsible for Brittle Bone Disease 2Health News:Researchers Discovered the Gene Responsible for Brittle Bone Disease 3Health News:Inflammatory Genes Linked to Salt-Sensitive Hypertension 2Health News:Inflammatory Genes Linked to Salt-Sensitive Hypertension 3
The Medtronic StableMapr catheter is intended for use in diagnostic electrophysiologic procedures. These catheters are designed for recording intracardiac electrograms and temporary pacing associated
The Valve Mapper Steerocath-Dx has a unique "peanut" shaped tip. It is designed to conform to the anatomy during mapping procedures. Both 8F/8mm and 8F/6mm tips are available.
...heter is specifically designed for use with our CA...able NAVI-STAR catheter houses a Biosense Webster ..., exact location points from within the heart whil...rmation. The NAVI-STAR electro-anatomical navigati...
For Tricuspid Mapping. Biosense Webster offers a complete line of specialty 20-pole catheters for mapping in the atrium. The HALO XP 20-pole deflectable catheter is designed for simple placement and
Medicine Products: